ONCO STARTUP SUMMIT : Le vécu de la startup “Quelle situation et perspective 2024 du marché de l’investissement pour les startups en oncologie”
REPLAY “REGARDS CROISES”
🎧Paul Bravetti, CEO Brenus Pharma – Taking the risk of launching a biotech company – Pharma Minds Podcast
LISTEN PODCAST “Paul a commencé sa carrière dans les Big Pharma (Servier, Takeda oncologie) il est parti à l’international, pour finalement se lancer dans une aventure entrepreneuriale en Biotech. Son goût de la science, du médical et de l’innovation au service des patients l’ont poussé à faire le grand saut. Depuis 3 ans, il alterne entre levées de fonds, construction d’une équipe engagée et développement du protocole pré-clinique au service de son candidat vaccin en oncologie. Nathalie Lahitte et Paul ont parlé de : -Son choix d’aller en Asie, -Travailler son switch médical -L’intrapreneuriat dans les Big Pharma -Devenir pionnier dans la recherche médicale -Préparer le pipeline de demain des Big Pharma -Comment décider de se lancer dans une aventure si risquée Témoignage rare sincère et suffisamment transparent pour donner envie de se plonger dans son mindset d’entrepreneur français au service de la science. Citation “La vraie générosité envers l’avenir consiste à tout donner au présent” Albert Camus.
[📢Brenus annouces its international scientific committee]
LYON, (FRANCE), June 7th, 2023, – Following the American Society of Clinical Oncology’s, Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow”, the company highlighted its international scientific committee. View PDF
ASCO annual meeting 2023
Efficacy of STC-1010, a new allogenic cancer vaccine in colorectal cancer models F.Ghiringhelli et al, J Clin Oncol, 2023 (suppl 16; abstr e14661) 10.1200/JCO.2023.41.16_suppl.e14661 Link to Abstract
[📢 BRENUS Pharma unveils groundbreaking preclinical results for STC-10101 , a promising new drug candidate targeting Colorectal Cancer & Solid Tumors. #AACR23]
DOWNLOAD PR
AACR Annual meeting 2023
Inovative in vivo (in ovo) CAM model to predict efficacy and mode of action of a new antitumor vaccine stc-1010 on human colorectal adenocarcinoma F. Ghiringhelliet al, Cancer Res 2023; 6791. https://doi.org/10.1158/1538-7445.AM2023-6791 Link to poster STC-1010 a new therapeutic vaccine promotes tumor cell death A. Italiano et al, Cancer Res 2023; LB224.https://doi.org/10.1158/1538-7445.AM2023-LB224 Link to Poster
[📢 French Blood Establishment (EFS) & Brenus Pharma partner for the GMP production of STC-1010, an innovative therapy against colorectal cancer]
French Blood Establishment (EFS) & Brenus Pharma partner for the GMP production of STC-1010, an innovative therapy against colorectal cancer – DOWNLOAD PR
[📢Pharma announces its Strategic Committee supporting & ensuring its value-creating strategic plan]
DOWNLOAD PRESS RELEASE
[📢Brenus Pharma and InSphero receive €1.5 million in grants from the European EUROSTARS fund for the development of a companion test for the next-generation cancer cell immunotherapy STC-1010]
DOWNLOAD PR Brenus Pharma and InSphero receive €1.5 million in grants from the European EUROSTARS fund for the development of a companion test for the next-generation cancer cell immunotherapy STC-1010.
[📢Brenus Pharma and InSphero receive €1.5 million in grants from the European EUROSTARS fund for the development of a companion test for the next-generation cancer cell immunotherapy STC-1010]
Brenus Pharma and InSphero receive €1.5 million in grants from the European EUROSTARS fund for the development of a companion test for the next-generation cancer cell immunotherapy STC-1010 DOWNLOAD PR